Needham & Company LLC Lowers CorMedix (NASDAQ:CRMD) Price Target to $14.00

CorMedix (NASDAQ:CRMD) had its price objective reduced by research analysts at Needham & Company LLC from $15.00 to $14.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s target price would suggest a potential upside of 116.72% from the stock’s current price.

CRMD has been the topic of a number of other research reports. Royal Bank Of Canada set a $13.00 price target on shares of CorMedix and gave the stock an “outperform” rating in a report on Wednesday, January 21st. HC Wainwright decreased their price objective on CorMedix from $18.00 to $13.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Zacks Research downgraded CorMedix from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of CorMedix in a research report on Wednesday, January 21st. Finally, Truist Financial set a $16.00 price target on CorMedix in a research note on Thursday, January 8th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, CorMedix currently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

CorMedix Trading Up 2.5%

Shares of CorMedix stock opened at $6.46 on Thursday. The company has a quick ratio of 1.73, a current ratio of 1.94 and a debt-to-equity ratio of 0.39. CorMedix has a 12-month low of $5.60 and a 12-month high of $17.43. The company has a market capitalization of $508.98 million, a price-to-earnings ratio of 3.23 and a beta of 1.31. The firm’s 50-day moving average price is $8.05 and its two-hundred day moving average price is $10.35.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.86 by ($0.70). The business had revenue of $128.62 million for the quarter, compared to the consensus estimate of $127.02 million. CorMedix had a return on equity of 61.63% and a net margin of 52.31%.CorMedix’s quarterly revenue was up 312.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.22 earnings per share. On average, analysts forecast that CorMedix will post -0.32 earnings per share for the current fiscal year.

CorMedix announced that its Board of Directors has approved a stock buyback plan on Monday, February 2nd that permits the company to repurchase $75.00 million in shares. This repurchase authorization permits the company to repurchase up to 12.3% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling

In other CorMedix news, Director Steven W. Lefkowitz sold 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $11.88, for a total transaction of $475,200.00. Following the completion of the sale, the director directly owned 80,498 shares of the company’s stock, valued at approximately $956,316.24. The trade was a 33.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Alan W. Dunton sold 20,000 shares of the firm’s stock in a transaction on Tuesday, December 30th. The shares were sold at an average price of $13.00, for a total value of $260,000.00. Following the transaction, the director owned 40,250 shares in the company, valued at approximately $523,250. This trade represents a 33.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 90,000 shares of company stock valued at $1,095,200. 3.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On CorMedix

A number of hedge funds and other institutional investors have recently modified their holdings of CRMD. Deerfield Management Company L.P. purchased a new stake in shares of CorMedix during the third quarter valued at approximately $38,656,000. Marshall Wace LLP boosted its position in CorMedix by 1,019.2% in the second quarter. Marshall Wace LLP now owns 2,579,976 shares of the company’s stock worth $31,785,000 after purchasing an additional 2,349,451 shares during the last quarter. UBS Group AG boosted its position in CorMedix by 295.3% in the third quarter. UBS Group AG now owns 1,090,908 shares of the company’s stock worth $12,687,000 after purchasing an additional 814,964 shares during the last quarter. Jump Financial LLC bought a new position in CorMedix in the 3rd quarter valued at $9,003,000. Finally, Goldman Sachs Group Inc. increased its holdings in CorMedix by 259.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 828,781 shares of the company’s stock worth $9,639,000 after buying an additional 597,971 shares during the last quarter. Hedge funds and other institutional investors own 34.18% of the company’s stock.

CorMedix News Summary

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Q4 and full‑year results showed very strong top‑line growth and profitability (Q4 net revenue $128.6M; pro forma FY‑2025 net revenue $401.3M; adjusted EBITDA $77.2M; net income $14.0M), which supports valuation if growth persists. Earnings Release
• Positive Sentiment: Company discussion of a share buyback program and evolving REZZAYO data may reduce float and improve the risk/return profile, which investors view positively. Buyback & REZZAYO Article
• Neutral Sentiment: Multiple transcripts and conference‑call coverage are available for investors who want details from management on results, guidance and commercial progress. Earnings Call Transcript (Seeking Alpha)
• Neutral Sentiment: Short‑interest data in the feeds shows zeros/NaN values and a 0.0 days‑to‑cover metric—this appears to be a reporting glitch and is not a reliable signal. (No actionable short‑interest change confirmed.)
• Negative Sentiment: Reported EPS missed consensus by a wide margin, which triggered sell‑side and media coverage noting the stock decline after earnings; that EPS miss is the primary near‑term negative driver. Stock Drops After Earnings (Invezz)
• Negative Sentiment: FY‑2026 revenue guidance was provided at $300M–$320M, which sits around or slightly below some Street estimates (~$309.5M) and may temper near‑term upside if investors expected a more aggressive outlook. Press Release / Guidance
• Negative Sentiment: Needham cut its price target from $15 to $14 (but kept a Buy rating), a modest negative signal that may limit near‑term analyst‑driven upside. Needham PT Note

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.